Orion Corporation: Managers' transactions – Kari Jussi Aho

ORION CORPORATIONMANAGERS' TRANSACTIONS27 JULY 2023 at 17.15 EEST                        Orion Corporation: Managers' transactions – Kari Jussi Aho Orion Corporation has received the following disclosure under Market Abuse Regulation (EU) No 596/2014, regarding transactions with shares and linked securities in Orion Corporation made by managers and their closely associated persons.Orion Oyj - Managers' Transactions____________________________________________Person subject to...

ORION CORPORATION
MANAGERS' TRANSACTIONS
27 JULY 2023 at 17.15 EEST              
        

Orion Corporation: Managers' transactions – Kari Jussi Aho

Orion Corporation has received the following disclosure under Market Abuse Regulation (EU) No 596/2014, regarding transactions with shares and linked securities in Orion Corporation made by managers and their closely associated persons.

Orion Oyj - Managers' Transactions

____________________________________________

Person subject to the notification requirement
Name: Kari Jussi Aho
Position: Member of the Board/Deputy member
Issuer: Orion Oyj
LEI: 74370029VAHCXDR7B745
Notification type: INITIAL NOTIFICATION
Reference number: 35946/16/18

____________________________________________

Transaction date: 2023-07-27
Venue: NASDAQ HELSINKI LTD (XHEL)
Instrument type: SHARE
ISIN: FI0009014369
Nature of transaction: ACQUISITION

Transaction details
(1): Volume: 6000 Unit price: 35.72 EUR

Aggregated transactions (1):
Volume: 6000 Volume weighted average price: 35.72 EUR

Orion Corporation

Liisa Hurme President and CEO

Olli Huotari SVP, Corporate Functions

                                                

Publisher:
Orion Corporation
Communications
Orionintie 1A, FI-02200 Espoo, Finland
http://www.orion.fi/en
http://www.twitter.com/OrionCorpIR

Orion is a globally operating Finnish pharmaceutical company – a builder of well-being. We develop, manufacture and market human and veterinary pharmaceuticals and active pharmaceutical ingredients. Orion has an extensive portfolio of proprietary and generic medicines and self-care products. The core therapy areas of our pharmaceutical R&D are oncology and pain. Proprietary products developed by Orion are used to treat cancer, neurological diseases and respiratory diseases, among others. Orion's net sales in 2022 amounted to EUR 1,341 million and the company had about 3,500 employees at the end of the year. Orion's A and B shares are listed on Nasdaq Helsinki.